佐力藥業(300181.SZ):前三季度淨利預增52.07%-59.67%
格隆匯8月30日丨佐力藥業(300181.SZ)公佈2022年前三季度業績預吿,報吿期歸屬於上市公司股東的淨利潤為盈利2.0億元–2.1億元,比上年同期增長52.07%-59.67%;扣除非經常性損益後的淨利潤為盈利1.939億元–2.051億元,比上年同期增長53.10%-61.94%。
公司核心產品烏靈膠囊、靈澤片銷售收入比去年同期有較大增長;同時中藥飲片及配方顆粒繼續加強業務拓展,銷售收入比去年同期有較好增長;受湖北聯盟集採影響,三季度百令片銷售有所影響。報吿期內,公司貸款規模有所降低導致利息費用減少,同時利息收入也有所增加,財務費用較去年同期降低。2022年1-9月,預計非經常性損益對歸屬於上市公司股東的淨利潤的影響金額約為490-610萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.